These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37817506)

  • 1. Assessing surrogacy using restricted mean survival time ratio for overall survival in liver cancer: a narrative review.
    Leung TH; Ho JC; Wang X; Pang H
    Chin Clin Oncol; 2023 Oct; 12(5):53. PubMed ID: 37817506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing surrogacy using restricted mean survival time ratio for overall survival in non-small cell lung cancer immunotherapy studies.
    Pang H; Yang G; Ho JC; Leung TH; Shi Q; Hu C; Stinchcombe TE; Wang X
    Chin Clin Oncol; 2022 Feb; 11(1):7. PubMed ID: 35255696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.
    Pak K; Uno H; Kim DH; Tian L; Kane RC; Takeuchi M; Fu H; Claggett B; Wei LJ
    JAMA Oncol; 2017 Dec; 3(12):1692-1696. PubMed ID: 28975263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma.
    Cabibbo G; Celsa C; Enea M; Battaglia S; Rizzo GEM; Busacca A; Matranga D; Attanasio M; Reig M; Craxì A; Cammà C
    Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.
    Hua T; Gao Y; Zhang R; Wei Y; Chen F
    BMC Cancer; 2022 Sep; 22(1):1022. PubMed ID: 36171546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surrogacy of one-year survival for overall survival in advanced hepatocellular carcinoma.
    Jin Y; Ren H; Yue Q; Wu W; Liu C; Guo Y; Zhao P
    BMC Cancer; 2024 Feb; 24(1):258. PubMed ID: 38395854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
    Wang X; Wang X; Hodgson L; George SL; Sargent DJ; Foster NR; Ganti AK; Stinchcombe TE; Crawford J; Kratzke R; Adjei AA; Kindler HL; Vokes EE; Pang H
    Oncologist; 2017 Feb; 22(2):189-198. PubMed ID: 28188257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Wang ZX; Wu HX; Xie L; Wang YN; Yang LP; He MM; Luo HY; Ding PR; Xie D; Chen G; Li YH; Wang F; Xu RH
    JAMA Netw Open; 2019 May; 2(5):e193433. PubMed ID: 31050784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
    Zhang S; Li S; Cui Y; Zhao P; Sun X; Cheng Y
    Front Oncol; 2021; 11():696010. PubMed ID: 34336683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in Treatment Effect Size Between Overall Survival and Progression-Free Survival in Immunotherapy Trials: A Meta-Epidemiologic Study of Trials With Results Posted at ClinicalTrials.gov.
    Tan A; Porcher R; Crequit P; Ravaud P; Dechartres A
    J Clin Oncol; 2017 May; 35(15):1686-1694. PubMed ID: 28375786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: Literature-based meta-analysis.
    Kataoka K; Nakamura K; Mizusawa J; Kato K; Eba J; Katayama H; Shibata T; Fukuda H
    Eur J Surg Oncol; 2017 Oct; 43(10):1956-1961. PubMed ID: 28747249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis.
    Ajani JA; Leung L; Singh P; Kurt M; Kim I; Pourrahmat MM; Kanters S
    Eur J Cancer; 2022 Jul; 170():119-130. PubMed ID: 35605522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
    Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
    Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
    Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
    Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.
    Foster NR; Renfro LA; Schild SE; Redman MW; Wang XF; Dahlberg SE; Ding K; Bradbury PA; Ramalingam SS; Gandara DR; Shibata T; Saijo N; Vokes EE; Adjei AA; Mandrekar SJ
    J Thorac Oncol; 2015 Jul; 10(7):1099-106. PubMed ID: 26134227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time.
    Rahmadian AP; Delos Santos S; Parshad S; Everest L; Cheung MC; Chan KK
    J Natl Compr Canc Netw; 2020 Mar; 18(3):278-285. PubMed ID: 32135516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis.
    Ghali F; Zhao Y; Patel D; Jewell T; Yu EY; Grivas P; Montgomery RB; Gore JL; Etzioni RB; Wright JL
    Eur Urol Open Sci; 2023 Jan; 47():58-64. PubMed ID: 36601043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation.
    Nocera L; Fallara G; Raggi D; Belladelli F; Robesti D; Montorsi F; Karakiewicz PI; Malavaud B; Ploussard G; Necchi A; Martini A
    Front Oncol; 2022; 12():955894. PubMed ID: 36132135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials.
    Zhang Z; Pan Q; Lu M; Zhao B
    EClinicalMedicine; 2023 Sep; 63():102156. PubMed ID: 37600482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
    Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
    BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.